Attached files
| file | filename |
|---|---|
| EX-10.1 - EXHIBIT 10.1 - AVADEL PHARMACEUTICALS PLC | tv486818_ex10-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 22, 2018
AVADEL PHARMACEUTICALS PLC
(Exact name of registrant as specified in its charter)
| Ireland | 001-37977 |
98-1341933 |
|
(State or Other Jurisdiction |
(Commission File Number) | (I.R.S. Employer Identification No.) |
|
Block 10-1 Blanchardstown Corporate Park, Ballycoolin Dublin 15, Ireland |
Not Applicable | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: +353 1 485 1200
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 1.01 | Entry into a Material Definitive Agreement. |
Letter Agreement
On February 22, 2018, Avadel Pharmaceuticals plc (the “Company”) entered into a letter agreement (the “Letter Agreement”) with Breaking Stick Holdings, LLC (“Breaking Stick”). The Letter Agreement, among other things, modified certain procedures regarding the exercise of certain warrants held by Breaking Stick for the purchase of American Depositary Shares (ADSs) of the Company, including allowing Breaking Stick to make Cashless Exercises (as defined in the warrants) during the remaining term of the warrants. The foregoing summary of the Letter Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the complete text of the Letter Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
| 10.1 | Letter Agreement, dated February 22, 2018, between Breaking Stick Holdings, LLC and Avadel Pharmaceuticals plc |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AVADEL PHARMACEUTICALS PLC | |||
| By: | /s/ Phillandas T. Thompson | ||
| Phillandas T. Thompson | |||
Senior Vice President,General Counsel and Corporate Secretary |
|||
| Date: February 22, 2018 | |||
Exhibit Index
| 10.1 | Letter Agreement, dated February 22, 2018, between Breaking Stick Holdings, LLC and Avadel Pharmaceuticals plc |